You are here

Single-Tablet HIV Regimen Submitted for FDA Review

Treatment combines dolutegravir, abacavir, and lamivudine (October 22)

A new drug application (NDA) has been submitted to the FDA for an investigational single-tablet regimen that combines dolutegravir, abacavir, and lamivudine (ViiV Healthcare) for the treatment of patients with human immunodeficiency virus-1 (HIV-1) infection.

The NDA submission follows the approval of dolutegravir (Ticivay, ViiV Healthcare) by the FDA in August 2013 for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg (approximately 88 lbs).

The new submission was based on data from one pivotal phase III study of dolutegravir, supported by three other phase III/IIIb studies that evaluated the safety and efficacy of this regimen. The submission also included pivotal data on the bioequivalence of dolutegravir, abacavir, and lamivudine when taken as a single-tablet regimen compared with the administration of dolutegravir and abacavir/lamivudine as separate components. An additional 48-week phase IIIb/IV study of this single-tablet regimen in treatment-naïve HIV-positive women (the ARIA study) is ongoing.

A combination tablet containing abacavir and lamivudine is available in the U.S. under the brand name Epzicom (ViiV Healthcare).

Source: ViiV Healthcare; October 22, 2013.

Recent Headlines

Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
More research is needed to confirm the finding
A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients